retatrutide phase 2 results obesity nejm 2023 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Retatrutide, a TRIPLE agonist (GLP1,

The upper outer arm over the triceps area is the approved injection site, though most manufacturers recommend having another person administer arm injections due to accessibility challenges

What Are Safer Alternatives to Retatrutide

Retatrutide: 40mg One sealed, pre-filled research device Fixed-volume research format Store refrigerated between 2C and 8C Do not freeze Research and development use only Why is Retatrutide studied

Some hair loss specialists recommend 1.2 to 1.5 grams per kilogram during active weight loss on GLP-1 medications

Staying informed about emerging options positions you to benefit from advances as they transition from research to clinical availability

No evidence of increase in calcitonin concentrations or development of C-cell malignancy in response to liraglutide for up to 5 years in the LEADER trial